

Accepted Manuscript

Nephrotoxicity of piperacillin-tazobactam combined with vancomycin:
Should it be a concern?

Cafer Balcı , Ömrüm Uzun , Mustafa Arıcı ,
Sibel Aşçıoğlu Hayran , Deniz Yüce , Serhat Ünal

PII: S0924-8579(18)30102-X
DOI: [10.1016/j.ijantimicag.2018.03.024](https://doi.org/10.1016/j.ijantimicag.2018.03.024)
Reference: ANTAGE 5415



To appear in: *International Journal of Antimicrobial Agents*

Received date: 2 January 2018
Revised date: 27 February 2018
Accepted date: 31 March 2018

Please cite this article as: Cafer Balcı , Ömrüm Uzun , Mustafa Arıcı , Sibel Aşçıoğlu Hayran , Deniz Yüce , Serhat Ünal , Nephrotoxicity of piperacillin-tazobactam combined with vancomycin: Should it be a concern?, *International Journal of Antimicrobial Agents* (2018), doi: [10.1016/j.ijantimicag.2018.03.024](https://doi.org/10.1016/j.ijantimicag.2018.03.024)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Highlights

- **Highlights** The risk of AKI in combination of piperacillin-tazobactam and vancomycin was 3.5 times higher than vancomycin monotherapy.
- Piperacillin-tazobactam and vancomycin combination should be used cautiously in patients with a high likelihood of developing renal failure.
- Clinicians should be aware of concomitant nephrotoxic medication in order to limit the increased AKI risk with co-administration of piperacillin-tazobactam and vancomycin.

Download English Version:

<https://daneshyari.com/en/article/8738423>

Download Persian Version:

<https://daneshyari.com/article/8738423>

[Daneshyari.com](https://daneshyari.com)